Olvanil Reduces Subcutaneous Fat Accumulation and Lipogenic Gene Expression, Without Alleviating Hepatic Oxidative Stress or Histopathological Alterations in Mice with Metabolic Dysfunction-Associated Steatotic Liver Disease
Elda Cristina Villaseñor-Tapia, David Alejandro Curiel-Pedraza, Edgar Rubén Mendieta-Condado, Jorge Alberto Rodríguez-González, Alejandro Arturo Canales-Aguirre, Edwin Estefan Reza-Zaldívar, Ana Laura Márquez-Aguirre
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excess intrahepatic lipid accumulation due to lipid overflow and synthesis, as well as impaired lipid oxidation. Olvanil (OLV) is a nonpungent capsaicin analog that has previously been shown to have anti-obesity effects in diet-induced obesity models. Nevertheless, its effects on fatty liver remain unclear. In this study, we evaluated the potential of OLV to address lipid metabolic dysfunction and MASLD-related hepatic abnormalities. C57BL/6 mice were fed a high-fat/high-fructose diet for 24 weeks, with or without OLV (25 mg/kg/day) administered by oral gavage for the last 8 weeks. We primarily evaluated the effects of OLV on liver function markers and the hepatic expression of key genes involved in lipid metabolism to assess its potential in reducing MASLD progression. We confirmed that OLV promoted lipolysis in adipocytes and significantly reduced body weight gain and fat accumulation, particularly in subcutaneous adipose tissue. At the molecular level, we demonstrated that OLV reduced the expression of lipogenic genes (